Celgene
| Type | Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 1986 (1986) |
| Founder | Sol J. Barer |
| Headquarters | Summit, New Jersey, U.S. |
| Key people | Robert J. Hugin (Executive Chairman) Mark Alles (CEO) |
| Products | Revlimid Abraxane Pomalyst/Imnovid Thalomid Idhifa |
| Revenue |  $15.281 billion (2018) |
| Net income | $4.046 billion (2018) |
| Total assets | $35.480 billion (2018) |
| Total equity |  $6.161 billion (2018) |
| Number of employees | 8,852 (2018) |
| Parent | Bristol Myers Squibb |
| Website | www.bms.com |
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).
For detailed contact information visit location pages below.
Celgene's locations around the world
Clinical Trials sponsored by Celgene
-
CelgeneCelgene CorporationCompletedLymphoma | CancerUnited States, United Kingdom
-
Celgene CorporationCompleted
-
Celgene CorporationCompletedLow- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)United States
-
Celgene CorporationTerminatedColorectal CancerAustralia, Belgium, Germany, Italy, Spain, Sweden
-
Celgene CorporationCompletedMyelodysplastic SyndromesUnited States, Denmark, Australia, Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
-
Celgene CorporationCompletedMultiple MyelomaIreland, Spain, Australia, Austria, United Kingdom
-
Celgene CorporationCompletedSmall Cell Lung CancerUnited States
-
Celgene CorporationWithdrawnMetastatic Breast CancerUnited States
-
Celgene CorporationCompletedNeoplasms | FatigueUnited States
-
Celgene CorporationCompletedMyelodysplastic SyndromesUnited States